

LETTER - CLINICAL

A case of eosinophilic annular erythema as a presenting sign for primary biliary cholangitis[☆]



Dear Editor,

Eosinophilic Annular Erythema (EAE) is a rare skin condition that presents as a figurate erythema with an unpredictable clinical course. Whether it represents an isolated entity, or a variant of Wells Syndrome (WS) remains controversial, but its diagnosis is significant for its relationship with several systemic diseases and malignancies. We present the case of a patient presenting with EAE that led to the diagnosis of Primary Biliary Cholangitis (PBC), an association not reported in the literature.

A 62-year-old woman with a history of hypercholesterolemia consulted for intensely pruritic skin lesions that developed over the last month on her extremities and trunk. Additional history of new medications, changes in personal products, insect bites, and new sexual contacts was noncontributory. On systemic anamnesis, she referred intermittent abdominal pain centered on hypogastrium, asthenia, diarrhea and a non-intentional weight loss of 5 kg over the last year. Fever, choloria, or acholia were not present. Physical examination showed multiple erythematous annular plaques with elevated edges and central dusky hyperpigmentation on the lower and upper limbs and trunk (Fig. 1). Punch biopsies revealed deep and superficial perivascular lymphocytic infiltrate with numerous eosinophils and flame figures (Fig. 2), supporting the diagnosis of EAE. Laboratory tests were remarkable for positive anti-mitochondrial M2 antibodies at a 1:640 titer, cholestatic pattern (alkaline phosphatase, 108 UI/mL; gamma-glutamyl transpeptidase, 172 UI/mL; normal values of aspartate aminotransferase, alanine aminotransferase and bilirubin) and normal eosinophil counts. Abdominal and endoscopic ultrasounds ruled out mechanical bile duct obstruction, mass lesions and abnormalities of the gallbladder, leading to the diagnosis of PBC. The patient improved considerably on oral prednisone (30 mg/day) but experienced a flare when the medication was tapered. Ursodeoxycholic acid was initiated (900 mg/day) after the diagnosis of PBC without relapses of skin lesions and gastrointestinal symptoms after corticosteroid discontinuation and a 9-month follow-




Figure 1 Annular and arcuate erythematous plaques with a dusky pigmented center on the lower limbs (A). Detailed view of the lesions on the thighs (B).

up. On laboratory testing, serum hepatic enzymes were also reduced to normal levels.

EAE is an eosinophilic, chronic, relapsing and remitting skin condition that clinically presents as urticarial papules and plaques on the trunk and extremities with slowly expanding arcuate or annular elevated edges leaving a pigmented center.¹ Initially described in pediatric patients as annular erythema of infancy,² it remains unclear if EAE represents a subset of WS (eosinophilic cellulitis) or a separate entity itself. Histopathologic findings include superficial and deep perivascular lymphocytic infiltrate with numerous eosinophils and, rarely, vacuolar degeneration of the basal layer.³ Even if it was believed that EAE could be differentiated from Wells syndrome by the absence of “flame figures”, multiple reports, including our case, have proven it wrong.⁴

When spontaneous healing does not occur, treatment is often effective with topical or oral corticosteroids and antimalarial drugs but relapses after discontinuation are common.⁵ Other treatment options reported in the literature are dapsone, specific cancer-associated treat-

[☆] Study conducted at the University General Hospital of Albacete, Albacete, Castilla-La Mancha, Spain.




Figure 2 (A e B) Deep and superficial perivascular lymphocytic infiltrates with numerous eosinophils and flame figures (arrow) (C). Hematoxylin & eosin $\times 100$ (A), $\times 200$ (B–C).

ment, methotrexate, anti-histamines, cyclosporine and minocycline. Isolated cases have successfully responded to dupilumab (IL-4 and IL-3 inhibitor) and benralizumab (IL-5 inhibitor) and this is not surprising since they are T-helper 2 type cytokines inhibitors, and a dysregulated tissue eosinophilia is thought to play an important role in EAE pathogenesis.⁶

EAE has been associated with thymoma, clear cell renal carcinoma, metastatic prostate cancer, autoimmune thyroid disease, borreliosis, chronic gastritis caused by *Helicobacter pylori*, diabetes mellitus, hepatitis C infection, chronic kidney disease, eosinophilic granulomatosis with polyangiitis, asthma, autoimmune pancreatitis and autoimmune hepatitis.⁷ Lower relapse rates and prolonged remission periods have been observed when these associated diseases are managed properly.⁴ To our knowledge, the association with PBC and EAE has not been reported.

Although the etiology of EAE remains unclear, it is suggested that it may be the result of a hypersensitivity reaction to an unidentified antigen.⁸ In the case of PBC, recent studies have demonstrated that serum CCL11, CCL24 and CCL26 are potent eosinophil-attractive chemokines that are up-regulated in PBC and could explain the possible association of PBC and the occurrence of eosinophilic dermatoses such as EAE in our patient.⁹ In addition, the improvement of the PBC course and the resolution of skin lesion relapses with ursodeoxycholic acid provide extra support for this association in the present case.

In conclusion, we present a case of EAE that led to the diagnosis of PBC. Whether EAE is a distinct entity or not, its presence should raise awareness of an underlying systemic

disease and a thorough patient work-up should be carried out.

Financial support

None declared.

Authors' contributions

Pablo López Sanz: Study: Concept and design, data collection, or analysis and interpretation of data, writing of the manuscript, critical review of the literature, intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases.

Noelia de Sande Rivera: Study concept and design, critical review of the literature, intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases.

Claudia Guerrero Ramírez: Effective participation in the research guidance, intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases.

Silvia Manso Córdoba: Effective participation in the research guidance, intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases.

Carlota Rodríguez de Vera Guardiola: Data collection, or analysis and interpretation of data, effective participation in the research guidance.

Eduardo Escario Travesedo: Effective participation in the research guidance, intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases, final approval of the final version of the manuscript.

Conflicts of interest

None declared.

References

1. Heras MO, Muñoz NP, Sancho MI, Millet PU. Eosinophilic annular erythema in adults: report of two cases and review of the literature. *An Bras Dermatol*. 2017;92:65–8.
2. Fania L, Provini A, Rota L, Mazzanti C, Ricci F, Panebianco A, et al. Eosinophilic annular erythema: report of four cases. *Dermatol Ther*. 2020;33:14369.
3. Kim YS, Song YM, Seo HM, Bang CH, Lee JH, Lee JY, et al. Eosinophilic annular erythema associated with churg-strauss syndrome. *Ann Dermatol*. 2017;29:813–4.
4. El-Khalawany M, Al-Mutairi N, Sultan M, Shaaban D. Eosinophilic annular erythema is a peculiar subtype in the spectrum of Wells syndrome: a multicentre long-term follow-up study. *J Eur Acad Dermatol Venereol*. 2013;27:973–9.
5. Chastagner M, Shourik J, Jachiet M, Battistella M, Lefevre G, Gibier JB, et al. Treatment of eosinophilic annular erythema: retrospective multicenter study and literature review. *Ann Dermatol Venereol*. 2022;149:123–7.
6. Moro-Bolado F, Martínez-Montalvo L, Al-Wattar-Ceballos O, Galindo-Bonilla PÁ, García-Arpa M. Treatment of eosinophilic annular erythema with benralizumab. *JAMA Dermatol*. 2023;159:564–6.
7. Awosika O, Totoraitis K, Eleryan M, Rengifo-Pardo M, Ehrlich A. A case of eosinophilic annular erythema as a presenting sign for autoimmune hepatitis. *JAAD Case Rep*. 2017;4:84–6.
8. Prajapati V, Cheung-Lee M, Schloss E, Salopek TG. Spontaneously resolving eosinophilic annular erythema. *J Am Acad Dermatol*. 2012;67:e75–7.
9. Lin F, Shi H, Liu D, Zhang Z, Luo W, Mao P, et al. Association of CCL11, CCL24 and CCL26 with primary biliary cholangitis. *Int Immunopharmacol*. 2019;67:372–7.

Pablo López Sanz ^{ID a,*}, Noelia de Sande Rivera ^{ID b},
Claudia Guerrero Ramírez ^{ID a}, Silvia Manso Córdoba ^{ID a},
Carlota Rodríguez de Vera Guardiola ^{ID c},
Eduardo Escario Travesedo ^{ID a}

^a Department of Dermatology, University General Hospital of Albacete, Albacete, Castilla-La Mancha, Spain

^b Department of Gastroenterology and Hepatology, University General Hospital of Albacete, Albacete, Castilla-La Mancha, Spain

^c Department of Pathology, University General Hospital of Albacete, Albacete, Castilla-La Mancha, Spain

* Corresponding author.

E-mail: lopezsanzpablo@gmail.com (P. López Sanz).

Received 18 March 2023; accepted 17 May 2023

Available online 6 August 2024

<https://doi.org/10.1016/j.abd.2023.05.014>

0365-0596/ © 2024 Sociedade Brasileira de Dermatologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

A case of psoriasiform eruption developed during imatinib therapy[☆]



Dear Editor,

Imatinib is the standard first-line systemic treatment for chronic myeloid leukemia and Gastrointestinal Stromal Tumor (GIST), targeting BCR-ABL and c-KIT tyrosine kinases, respectively. Imatinib-induced eruptions can present with a variety of skin manifestations, but cases with psoriasis/psoriasiform eruptions are rare. We herein report one such case with a review of the literature.

A 69-year-old man was referred to our department with a psoriasiform eruption. He had been treated with imatinib for GIST for the previous 2 years. Two months after the start of imatinib treatment at 400 mg/day, a rash appeared. Physical examination revealed red papules with scales of 2–4 mm in size on the trunk and limbs. In addition, the buttocks had a number of scaly erythema resembling psoriasis (Fig. 1A). A skin biopsy was performed from the scaly erythema of the lower leg (Fig. 1B). Histological findings revealed mild

epidermal proliferation with parakeratosis, and subepidermal dilatation of capillaries with perivascular infiltration of mononuclear cells, containing eosinophils (Fig. 1C). Blood test revealed that the patient's eosinophils were elevated between 10% and 15%. Based on the course of the disease, a diagnosis of drug eruption caused by imatinib was made. Treatment was begun with oral antihistamine and topical corticosteroids, and the skin rash improved (Fig. 1D). During the treatment period, imatinib was continued without dose reduction.

Cutaneous reactions are the most commonly reported nonhematological side effects, occurring in 9.5%–69% of patients.¹ Maculopapular or erythematous eruptions, edema, and periorbital edema are the most common adverse events observed. Severe drug eruptions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported. Imatinib potentially affects immune cells directly, and several cases showed improvement in psoriasis after the introduction of imatinib.^{2,3} By contrast, exacerbation of psoriasis or de novo development of psoriasiform rash have rarely been reported. As a pathogenetic mechanism, it has been reported that imatinib treatment reduced CD4+CD25+FoxP3+ regulatory T-cell (Treg) frequency and decreased immunosuppressive function.⁴ Therefore, reduced activation of Tregs by imatinib may contribute to the development of psoriasis or

[☆] Study conducted at the Fukushima Medical University, Fukushima, Japan.